# US 2012/0252022 A1 · Methods and compositions for the diagnosis and treatment of thyroid cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252022 A1
- Document ID: US20120252022A1
- Status: Published application
- Kind: A1
- Application number: 13/497,441
- Filed: 2010-09-21
- Published: 2012-10-04
- Earliest claimed: 2009-09-21
- Inventors: Paul Walfish; Ranju Ralhan
- Web page: https://patentgrep.com/patent/US20120252022A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for detecting, diagnosing and monitoring thyroid cancer in a subject are described comprising measuring in a sample from the subject markers including Ep-ICD and β-catenin. The invention also provides kits and compositions for carrying out the methods of the invention.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for diagnosing thyroid cancer in a subject comprising:
(a) detecting or identifying in a sample from the patient, levels of one or more thyroid cancer markers comprising Ep-ICD and, optionally EpEx;
(b) comparing the detected levels of the thyroid cancer markers with control levels, wherein a significant difference in the level of at least one of the thyroid cancer markers relative to the corresponding control level is indicative of thyroid cancer.

### Claim 3 (depends on 2)

The method of claim 2 wherein the subject is at risk of having thyroid cancer or in need of screening.

### Claim at position 4

-7. (canceled)

### Claim 8

A method for diagnosing the aggressiveness or metastatic potential of a thyroid cancer in a subject comprising:
(a) contacting a sample from the subject with an agent capable of detecting a thyroid cancer marker;
(b) detecting in the sample the thyroid cancer marker; and
(c) comparing the detected amount with an amount detected for a standard, wherein the thyroid cancer marker is Ep-ICD and optionally EpEx, wherein a higher level of Ep-ICD, optionally together with a lower level of EpEx correlates with a more aggressive or increased metastatic potential of thyroid cancer, while a lower level of Ep-ICD and optionally together with a higher level of EpEx correlates with a less aggressive or lower metastatic potential of thyroid cancer.

### Claim 9 (depends on 8)

A The method of claim 8, wherein the standard or control comprises levels or an amount detected in a subject with a lower grade of thyroid cancer.

### Claim 10 (depends on 8)

The method of claim 8, wherein the thyroid cancer is anaplastic thyroid cancer (ATC).

### Claim 11

A method for monitoring the progression of a thyroid cancer in a subject, the method comprising: (a) detecting in a sample from a patient at a first time point, a thyroid cancer marker; (b) repeating step (a) at a subsequent point in time; and (c) comparing levels detected in steps (a) and (b), and thereby monitoring the progression of the cancer, wherein the thyroid cancer marker is Ep-ICD and optionally EpEx.

### Claim 12 (depends on 2)

The method of claim 2 wherein the thyroid cancer marker is a polypeptide detected by the following steps:
(i) contacting the sample with a binding agent that specifically binds to the polypeptide or a part thereof; and
(ii) detecting in the sample an amount of polypeptide that binds to the binding agent relative to a predetermined standard.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The method of claim 12 wherein the binding agent is an antibody.

### Claim 15 (depends on 2)

A The method of claim 2, wherein the thyroid cancer marker is a polynucleotide.

### Claim 16 (depends on 15)

The method of claim 15 wherein the polynucleotide is mRNA or fragments thereof.

### Claim 17 (depends on 15)

The method of claim 15 wherein the polynucleotide is detected by
(i) contacting the sample with oligonucleotides that hybridize to the polynucleotides; and
(ii) detecting in the sample levels of nucleic acids that hybridize to the polynucleotides relative to a predetermined standard or cut-off value, and therefrom determining the presence or absence of thyroid cancer in the subject.

### Claim 18 (depends on 16)

The method of claim 16 wherein the mRNA is detected using an amplification reaction.

### Claim 19 (depends on 18)

The method of claim 18 wherein the amplification reaction is a polymerase chain reaction employing oligonucleotide primers that hybridize to the polynucleotides, or complements of such polynucleotides.

### Claim 20 (depends on 19)

The method of claim 19 wherein the polynucleotide is detected using RT-PCR.

### Claim 21 (depends on 16)

The method of claim 16 wherein the mRNA is detected using a hybridization technique employing oligonucleotide probes that hybridize to the polynucleotides or complements of such polynucleotides.

### Claim at position 19

-25. (canceled)

### Claim 26 (depends on 2)

The of claim 2, wherein the sample is obtained from tissues, extracts, cell cultures, cell lysates, lavage fluid or physiological fluids.

### Claim 27 (depends on 26)

The method of claim 26 wherein the sample is obtained from a tumor tissue.

### Claim at position 22

-31. (canceled)

### Claim 32 (depends on 2)

The method of claim 2, wherein the significant difference is a significant increase in the level of at least one cancer marker as compared to the control level.

### Claim 33 (depends on 2)

The method of claim 2, wherein the thyroid markers further comprise EpEx and wherein a significant decrease in the level of EpEx as compared to the control level is indicative of cancer and together with a significant increase in the level of Ep-ICD as compared to the control level is indicative of an aggressive cancer.

### Claim 34 (depends on 2)

The method of claim 2, wherein the control levels are levels detected in a healthy subject or from the subject at an earlier point in time.
